Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole
Status:
Terminated
Trial end date:
2015-11-05
Target enrollment:
Participant gender:
Summary
First study to test the validity of the treatment of idiopathic pulmonary fibrosis, which
causes inflammation and fibrosis (scarring) of the lung tissue, with cotrimoxazole.
Cotrimoxazole may improve the clinical course of the disease through eradication of
Pneumocystis jiroveci colonization and other mechanisms as inhibiting the activation of
alveolar macrophages and producing alterations in the surfactant system which favours the
persistent activation of the inflammatory response and the development of pulmonary fibrosis.
Phase:
Phase 3
Details
Lead Sponsor:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Collaborator:
Junta de Andalucia
Treatments:
Sulfamethoxazole Trimethoprim Trimethoprim, Sulfamethoxazole Drug Combination